Abattis Bioceuticals Corp  

(Public, CNSX:ATT)   Watch this stock  
Find more results for CNSX:FLU
0.000 (0.00%)
Feb 22 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.01 - 1.00
Open     -
Vol / Avg. 0.00/816,426.00
Mkt cap 18.13M
P/E     -
Div/yield     -
EPS -0.05
Shares 120.70M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -6062.27%
Operating margin - -6209.36%
EBITD margin - -3153.99%
Return on average assets -109.15% -148.29%
Return on average equity -160.29% -182.41%
CDP Score - -


104-9295 198 St
+1-604-3360881 (Phone)
+1-604-8881519 (Fax)

Website links


Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Officers and directors

Michael David Yung Chief Executive Officer
Rene David Chief Financial Officer, Chief Operating Officer
Christopher P. Cherry Corporate Controller
Age: 38
Hugh Oswald IR Contact Officer
James Irving Director
Shuang Xie Director
Guy P. Dancosse QC Independent Director
William Panenka Independent Director
Douglas J. Sorocco Independent Director